Federal Grant Award Summary

Cincinnati Children's Hospital Medical Center received a $910,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to define the contemporary natural history and therapeutics impact on cardiomyopathy in Duchenne muscular dystrophy. The award, initiated July 15, 2026, with a completion date of July 14, 2029, supports a three-year research initiative addressing cardiac complications associated with this severe inherited muscular disorder. The research will be conducted at Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio, leveraging the institution's established expertise in pediatric clinical research and translational biomedical research.

This DHA-funded project aligns with the Military Medical Research and Development program's mission to support basic and applied biomedical research addressing conditions affecting the military population and broader public health. Cincinnati Children's will deliver research products focused on understanding the disease progression and natural history of Duchenne muscular dystrophy-related cardiomyopathy and evaluating therapeutic interventions to mitigate cardiac decline in this patient population. As a leading pediatric research institution with significant federal research portfolio experience, particularly through the National Institutes of Health and related agencies, Cincinnati Children's brings substantial institutional capacity to advance understanding of this debilitating condition.